FDA Adverse Event Injury Summary report: N

ONYX

MDR report key: 20637909 · Received November 8, 2024

Report

Report Number
2029214-2024-02095
Event Type
Injury
Date Received
November 8, 2024
Date of Event
July 7, 2023
Report Date
November 7, 2024
Manufacturer
MICRO THERAPEUTICS, INC. DBA EV3
Product Code
MFE
Adverse Event
Yes
Report Source
Manufacturer report
Reporter Location
NY, US
Reporter Occupation
PHYSICIAN
Health Professional
Yes

Narratives

Additional Manufacturer Narrative · 0

CONTINUATION OF D10: PRODUCT ID: UNK-NV-ONYX (UNKNOWN); G2: CITATION: AUTHORS: DEVARAJAN A, SCHUPPER A, ROSSITTO C, BONET J, SORSCHER M, VASAN V, MORGENSTERN, GHATANS, SHIGEMATSU T, BERENSTEIN A, FIFI J. USE OF A MINI BALLOON MICROCATHETER TO FACILITATE PENETRATION OF FINE VASCULAR NETWORKS AND CURATIVE EMBOLIZATION IN VEIN OF GALEN MALFORMATIONS. JOURNAL OF NEUROINTERVENTIONAL SURGERY 0:1¿9 2023. 10.1136/JNIS-2023-020577. EARLIEST DATE OF PUBLICATION USED FOR DATE OF EVENT NO UNIQUE DEVICE IDENTIFIER (SERIAL/LOT) NUMBERS WERE PROVIDED; WITHOUT THIS INFORMATION IT COULD NOT BE DETERMINED WHETHER THESE OBSERVATIONS HAVE BEEN PREVIOUSLY REPORTED. WITHOUT RETURN OF THE PRODUCT NO DEFINITIVE CONCLUSION CAN BE MADE REGARDING THE CLINICAL OBSERVATIONS. MEDTRONIC SUBMITS THIS REPORT TO COMPLY WITH FDA REGULATIONS 21 CFR PARTS 4 AND 803. MEDTRONIC HAS MADE REASONABLE EFFORTS TO PROVIDE AS MUCH RELEVANT INFORMATION AS IS AVAILABLE TO THE COMPANY AS OF THE SUBMISSION DATE OF THIS REPORT. THIS REPORT DOES NOT CONSTITUTE AN ADMISSION OR A CONCLUSION BY FDA, MEDTRONIC, OR ITS EMPLOYEES THAT THE DEVICE, MEDTRONIC, OR ITS EMPLOYEE CAUSED OR CONTRIBUTED TO THE EVENT DESCRIBED IN THE REPORT. ANY REQUIRED FIELDS THAT ARE UNPOPULATED ARE BLANK BECAUSE THE INFORMATION IS CURRENTLY UNKNOWN OR UNAVAILABLE. MEDTRONIC WILL SUBMIT A SUPPLEMENTAL REPORT IF ADDITIONAL RELEVANT INFORMATION BECOMES KNOWN.

Description of Event or Problem · 0

LITERATURE WAS REVIEWED REGARDING THE USE OF A MINI BALLOON MICROCATHETER TO FACILITATE PENETRATION OF FINE VASCULAR NETWORKS AND CU RATIVE EMBOLIZATION IN VEIN OF GALEN MALFORMATIONS. THE TIME FRAME OF THIS STUDY WAS FROM MAY 11, 2023, TO JULY 7, 2023. THE MEDTRONIC DEVICE USED WAS ONYX-18. EMBOLIZATION WITH ONYX-18 AND SIGNIFICANT NETWORK PENETRATION OCCURRED IN 17/17 USES. NO DEATHS OCCURRED IN THE STUDY POPULATION. AMONG PATIENT ADVERSE EVENTS INCLUDED: NEAR TIP ENTRAPMENT WITH LEA CAST DISPLACEMENT OCCURRED IN 1/17 USES. ANOTHER PATIENT EXPERIENCED POSTPROCEDURAL INTRAVENTRICULAR HEMORRHAGE REQUIRING A THIRD VENTRICULOSTOMY WITHOUT PERMANENT NEUROLOGIC DEFICIT.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1880955 ONYX AGENT, INJECTABLE, EMBOLIC MFE MICRO THERAPEUTICS, INC. DBA EV3 UNK-NV-ONYX UNKNOWN

Patients

Seq Age Sex Outcome Treatment
1 24 MO Unknown Required Intervention SEE H11